Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ACST)

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

GlobeNewswire February 12, 2024

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

GlobeNewswire February 1, 2024

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

GlobeNewswire December 13, 2023

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 13, 2023

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

GlobeNewswire October 23, 2023

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

GlobeNewswire October 4, 2023

Acasti Announces $7.5 Million Private Placement Equity Financing

GlobeNewswire September 26, 2023

Acasti to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2023

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 11, 2023
View More News ››

Opinion & Analysis (NDAQ:ACST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ACST)

the perfect situation

With a market cap  trading  under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you...
bingostar - December 22, 2022

RE:GTX-104 positive results

No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when...
Canadian_101 - November 21, 2022

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting...
bingostar - May 18, 2022

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today...
Betteryear2 - April 25, 2022

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never...
alanmar1 - April 3, 2022

RE:Over 200K on the bid, which is 1% of outstanding shares

Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low...
flush777 - January 5, 2022
View more Bullboard ››

Regenx Tech Corp.

Regenx Tech Corp.

Regenx Tech Corp. is a Canada-based company, which is engaged in development and commercialization of its environmentally ...
View More »